My Portfolio
My Watchlists
Profile & Performance
Smart Portfolio
Find & Follow Experts
Top Lists
Top Experts
Make Better, Data Driven Investment Decisions
TipRanks tools are all you need to make data-driven investment decisions, conduct comprehensive stock research, find new investment ideas, analyze your portfolio, and follow the best-performing Wall Street experts.
About Us
Plans & Pricing
Ovid Therapeutics Inc (OVID)
NASDAQ:OVID
OVID nasdaq
United States
Ovid Therapeutics

Ovid Therapeutics Stock Analysis & Ratings

Ovid Therapeutics Stock Analysis Overview

Smart Score
5
Neutral
1
2
3
4
5
6
7
8
9
10
Learn more about TipRanks Smart Score
The Ovid Therapeutics stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, Crowd Wisdom, Hedge Fund Activity, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.

Stock Chart

OVID

OVID Stock Stats

Previous Close$3.21
Open$3.21
Bid3.23 x 300
Ask3.4 x 100
Today’s Range$3.06 - $3.25
52-Week Range$2.25 - $4.80
Volume246.43K
Average Volume254.99K
Market Cap$219.94M
Beta1.70
P/E Ratio1.8
EPS1.78
Earnings DateMar 15, 2022

Company Description

Ovid Therapeutics Inc

Ovid Therapeutics, Inc. focuses on developing medicines for patients and families living with rare neurological disorders. The company was founded by Matthew During in April 2014 and is headquartered in New York, NY.
Sector
Healthcare
Industry
Biotechnology
CEO
Jeremy M. Levin
Employees
60
ISIN
US6904691010
Address
1460 Broadway, New York, NY, 10036, US

Financials


P/E Ratio Range

The price to earnings ratio. This is used by investors to assess a stock’s market price relative to its earnings.

OVID FAQ

What was Ovid Therapeutics’s price range in the past 12 months?
Ovid Therapeutics lowest stock price was $2.25 and its highest was $4.80 in the past 12 months.
    What is Ovid Therapeutics’s market cap?
    Ovid Therapeutics’s market cap is $219.94M.
      What is Ovid Therapeutics’s price target?
      The average price target for Ovid Therapeutics is $7.00. This is based on 1 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
      The highest analyst price target is $7.00 ,the lowest forecast is $7.00. The average price target represents 116.72% Increase from the current price of $3.23.
        What do analysts say about Ovid Therapeutics?
        Ovid Therapeutics’s analyst rating consensus is a ‘Moderate Buy. This is based on the ratings of 1 Wall Streets Analysts.
          When is Ovid Therapeutics’s upcoming earnings report date?
          Ovid Therapeutics’s upcoming earnings report date is Mar 15, 2022 which is in 97 days.
            How were Ovid Therapeutics’s earnings last quarter?
            Ovid Therapeutics released its earnings results on Nov 10, 2021. The company reported -$0.17 earnings per share for the quarter, beating the consensus estimate of -$0.189 by $0.019.
              Is Ovid Therapeutics overvalued?
              According to Wall Street analysts Ovid Therapeutics’s price is currently Undervalued.
                Does Ovid Therapeutics pay dividends?
                Ovid Therapeutics does not currently pay dividends.
                What is Ovid Therapeutics’s EPS estimate?
                Ovid Therapeutics’s EPS estimate for its next earnings report is not yet available.
                How many shares outstanding does Ovid Therapeutics have?
                Ovid Therapeutics has 68,090,000 shares outstanding.
                  What happened to Ovid Therapeutics’s price movement after its last earnings report?
                  Ovid Therapeutics reported an EPS of -$0.17 in its last earnings report, beating expectations of -$0.189. Following the earnings report the stock price went down -2.77%.
                    Which hedge fund is a major shareholder of Ovid Therapeutics?
                    Among the largest hedge funds holding Ovid Therapeutics’s share is Platinum Investment Management. It holds Ovid Therapeutics’s shares valued at 3M.

                      What's Included in PREMIUM?
                      Make informed decisions based on Top Analysts' activity
                      Know what industry insiders are buying
                      Get actionable alerts from top Wall Street Analysts
                      Find out before anyone else which stock is going to shoot up
                      Get powerful stock screeners & detailed portfolio analysis